¿Qué es la hiperplasia prostática?
Benign prostatic hyperplasia BPHalso called prostate enlargementis a noncancerous increase in size of the prostate gland. The cause is unclear. Treatment options including benigna prostatica displasia changes, medications, a benigna prostatica displasia of procedures, and surgery. About million men are affected globally. BPH is the most common cause of lower urinary tract symptoms LUTSwhich are divided into storage, voidingand symptoms which occur after urination.
BPH can be a progressive disease, especially if left untreated. Incomplete voiding results in residual urine or urinary stasis, which can lead to an increased risk of urinary tract infection. Most experts consider androgens testosterone benigna prostatica displasia related hormones to play a permissive benigna prostatica displasia in the development of BPH. This means that androgens must be present for BPH to occur, but do not necessarily directly cause the condition.
This is supported by evidence suggesting that castrated boys benigna prostatica displasia not develop BPH when they age. On the other hand, some studies suggest that administering exogenous testosterone is not associated with a significant increase in the risk of BPH symptoms, so the role of testosterone in prostate cancer and BPH is still unclear.
Further randomized controlled trials with more participants are needed to quantify any risk of giving exogenous testosterone. Dihydrotestosterone DHTa metabolite of testosterone, is a critical mediator of prostatic growth. DHT can act in an autocrine fashion on the stromal cells or in paracrine benigna prostatica displasia by diffusing into nearby epithelial cells.
In both of these cell types, DHT binds to nuclear androgen receptors and signals the transcription of growth factors that are mitogenic to the epithelial and stromal cells. DHT is ten times more potent benigna prostatica displasia testosterone because it dissociates from the androgen receptor more slowly. Testosterone promotes prostate cell proliferation,  but relatively low levels of serum testosterone are found benigna prostatica displasia patients with BPH.
While there is some evidence that estrogen may play a role in the cause of BPH, this effect appears to be mediated mainly through local conversion of androgens to estrogen in the prostate tissue rather than a direct effect of estrogen itself. InGat et al. Studies indicate that dietary patterns may affect development of BPH, but further research is needed to clarify any important relationship.
Men older than 60 in rural areas had very low rates of clinical BPH, while men living in cities and consuming more animal protein had a higher incidence. Benign prostatic hyperplasia is an age-related disease.
Misrepair-accumulation aging theory   suggests that development of benign prostatic hyperplasia is a consequence of fibrosis and weakening of benigna prostatica displasia muscular tissue in the prostate. However, repeated contractions and dilations of myofibers will unavoidably cause injuries and broken myofibers. Myofibers have a low potential for regeneration; therefore, collagen fibers need to be used to replace the broken myofibers.
Such misrepairs make the muscular tissue weak in functioning, and the fluid secreted by glands cannot be excreted completely. Then, the accumulation of benigna prostatica displasia in glands increases the resistance of muscular tissue during the movements of contractions and dilations, and more and more myofibers will be broken and replaced by collagen fibers.
As men age, the enzymes aromatase and 5-alpha reductase increase in activity. These enzymes are responsible for converting androgen hormones into estrogen and benigna prostatica displasiarespectively. This metabolism of androgen hormones leads to a decrease in testosterone but increased levels of DHT and estrogen. Both the glandular epithelial cells and the stromal cells including muscular fibers undergo hyperplasia in BPH. Anatomically the median and lateral lobes are usually enlarged, due to their highly glandular composition.
The anterior lobe has little in the way of glandular tissue and is seldom enlarged. Carcinoma of the prostate typically occurs in the posterior lobe — hence the ability to discern an irregular outline per rectal examination.
The earliest microscopic signs of BPH usually begin between the age of 30 and 50 years old in the PUG, which is posterior to the proximal urethra.
The clinical diagnosis of Benigna prostatica displasia is based on a history of LUTS lower urinary tract symptomsa digital rectal exam, benigna prostatica displasia exclusion of other causes of similar signs and symptoms. The degree of LUTS does not necessarily correspond to the size of the prostate.
An enlarged prostate gland on benigna prostatica displasia examination that is symmetric and smooth supports benigna prostatica displasia diagnosis of BPH. Urinalysis is typically performed when LUTS are present and BPH is suspected to evaluate for benigna prostatica displasia of a urinary tract infection, glucose in the urine suggestive of diabetesor protein in the urine suggestive of kidney disease. The differential diagnosis for LUTS is broad and includes various medical conditions, neurologic disorders, and other diseases of the bladder, urethra, and prostate such benigna prostatica displasia bladder cancerurinary tract infection, urethral strictureurethral calculi stoneschronic prostatitisand prostate cancer.
This may occur as a result of uncoordinated contraction of the bladder muscle or impairment in the timing of bladder muscle contraction and urethral sphincter relaxation. Certain medications benigna prostatica displasia increase urination difficulties by increasing bladder outlet resistance due to increased smooth muscle tone at the prostate or bladder neck and contribute to LUTS. Micrograph benigna prostatica displasia nodular hyperplasia left off center of the benigna prostatica displasia from a transurethral resection of the prostate TURP.
Normal non-neoplastic prostatic tissue NNT. Benign prostatic hyperplasia. High-grade prostatic intraepithelial neoplasia. Prostatic adenocarcinoma PCA. Lifestyle alterations to address the symptoms of Benigna prostatica displasia include physical activity,  decreasing fluid intake before bedtime, moderating the consumption of alcohol and caffeine-containing products and following a timed voiding schedule.
Patients can also attempt to avoid products and medications with anticholinergic properties benigna prostatica displasia may exacerbate urinary retention symptoms of BPH, including antihistaminesdecongestantsopioidsand tricyclic antidepressants ; however, changes in medications should be done with input from a medical benigna prostatica displasia.
Voiding position when urinating may influence urodynamic parameters urinary flow rate, voiding time, and post-void residual volume. This urodynamic profile is associated with a lower risk of urologic complications, such as cystitis and bladder stones.
They have a small to moderate benefit. Common side effects of alpha blockers benigna prostatica displasia orthostatic hypotension a head rush or dizzy spell when standing up or stretchingejaculation changes, erectile dysfunction headaches, nasal congestion, and weakness. The older, broadly non-selective alpha blocker medications such as phenoxybenzamine are not recommended for control of BPH.
Effects may take longer to appear than alpha blockers, but they persist for many years. Antimuscarinics such as tolterodine may also be used, especially in combination with alpha blockers. Phosphodiesterase-5 inhibitors such as sildenafil citrate show some symptomatic relief, benigna prostatica displasia a possible common cause with erectile dysfunction.
Food and Drug Administration approved tadalafil to treat the signs and symptoms of benign prostatic hyperplasia, and for the treatment of BPH and erectile dysfunction EDwhen the conditions occur simultaneously. Intermittent urinary catheterization is used to relieve the bladder in people with urinary retention. Self-catheterization is an option in BPH when it is difficult or impossible to completely empty the bladder.
If medical treatment is not effective, surgery may be performed. Surgical techniques used include benigna prostatica displasia following:. The latest alternative to surgical treatment is arterial embolizationan endovascular procedure performed in interventional radiology.
While benigna prostatica displasia remedies are commonly used, a review found them to be no better than placebo. The prostate gets larger in most men as they get older. Incidence rates increase from 3 cases per man-years at age 45—49 years, to 38 cases per benigna prostatica displasia by the age of 75—79 years. While the prevalence rate is 2. From Wikipedia, the free encyclopedia. Main article: Surgery for benign prostatic hyperplasia. Main article: Prostatic artery embolization.
September Archived from the original on 4 October Retrieved 19 October Annual Review of Medicine Review. Cochrane Database of Systematic Reviews. US National Library of Medicine. Archived from the original on 6 October Retrieved 26 October Benign prostatic hyperplasia and lower urinary tract symptoms". The New England Journal benigna prostatica displasia Medicine. The Journal of Urology. Prog Clin Biol Res. NCBI Bookshelf.
Archived from the original on 5 November Retrieved 2 February FDA — Drug Documents. Merck and Company. Archived PDF from the original on 3 March Retrieved 2 March World J Urol.
Nature Reviews Cancer. The Prostate. K M; Nanda, J. E; Habib, F. K Journal of Endocrinology. Asian Journal of Andrology. Annals of Saudi Medicine. Am J Clin Nutr.